Marinus Pharmaceuticals — Investor Presentation (March 2021)
58 slides from Marinus Pharmaceuticals's investor presentation, Mar 9, 2021
Slide 1: Corporate Overview March 2021
Corporate Overview March 2021 ©2021 Marinus Pharmaceuticals. All Rights Reserved I
Slide 2: Safe Harbor Statement
Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private
Slide 3: Ganaxolone Targets Synaptic & Extrasynaptic GABAA Receptors
Ganaxolone (GNX) Targets Synaptic & Extrasynaptic GABAA Receptors allopregnanolone 3 ©2021 Marinus Pharmaceuticals. All Rights Reserved I GNX is a synthetic analog of a positive allosteric GABAA receptor modulator with a well-defined MOA designed to treat patients suffering from epilepsy Ganaxolone
Slide 4: Corporate Strategy
Corporate Strategy Evaluation of IV and Oral Opportunities 4 ©2021 Marinus Pharmaceuticals. All Rights Reserved I • Expand clinical opportunities from refractory status epilepticus (RSE) to broader established status epilepticus (ESE) market • Initiate commercial plan • Create a global development s
Slide 5: Ganaxolone Development Pipeline
Ganaxolone Development Pipeline 5 ©2021 Marinus Pharmaceuticals. All Rights Reserved I
Slide 6: Orphan Epilepsy Franchise
Orphan Epilepsy Franchise
Slide 7: CDKL5 Deficiency Disorder
CDKL5 Deficiency Disorder “CDKL5 is painful. It’s a hard, sad at times, thing that we face. When you have a relationship with people like Marinus and their researchers, you are able to help be a driving force behind that work. - Karen Utley, Mother to Samantha, President of International Foundation
Slide 8: CDKL5 Deficiency Disorder (CDD)
CDKL5 Deficiency Disorder (CDD) • Genetic testing available 1Symonds JD 2019 Brain 8 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Cause •Mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome •Early-onset, treatment refractory seizures, & severe neuro-develo
Slide 9: Completed Global Phase 3 Trial Design
Completed Global Phase 3 Trial Design Historical Control 8 weeks Titration 4 weeks Titration 4 weeks Baseline 6 weeks Maintenance 13 weeks Open-Label Phase Double-Blind Phase Open-Label Phase Trial Details ► Evaluated the use of oral ganaxolone in children and young adults Global, double-blind, plac
Slide 10: Marigold Baseline Clinical Characteristics (n=101)
Marigold Baseline Clinical Characteristics (n=101) Baseline seizure burden and AED history highlights unmet need 10 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Characteristic Placebo (n=51) Ganaxolone (n=50) Total Baseline Primary Seizure Frequency, per 28 days (median, min-mix) 50.0 0.7 –
Slide 11: Ganaxolone Achieved Primary Efficacy Endpoint in Seizure Reduction
Ganaxolone Achieved Primary Efficacy Severity Endpoint in Seizure Reduction and Secondary Endpoint for Seizure 40 p = 0.002** 30 20 10 0 Ganaxolone Placebo *Hodges-Lehm an Estim ate of M edian Difference **W ilcoxon Rank-Sum Test 11 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Median Percent
Slide 12: Marigold Cumulative Response Curve
Marigold Cumulative Response Curve 12 ©2021 Marinus Pharmaceuticals. All Rights Reserved I % of Patients
Slide 13: Consistent Efficacy Signal Across the Broader CDD Population
Consistent Efficacy Signal Across the Broader CDD Population ► Ganaxolone demonstrated a similar efficacy signal across multiple subgroups related to baseline demographics and seizure frequency Supports beneficial effect in the U.S. patient population • 50 40 30 20 10 0 -10 Female (n=79) Male (n=21)
Slide 14: Phase 3 Safety Summary
Phase 3 Safety Summary Serious Treatment Emergent Adverse Events Treatment Emergent Adverse Events (TEAE) (n=50) Includes AEs that occurred >5% of subjects in ganaxolone arm and ganaxolone > placebo 14 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Preferred Term Placebo (n=51) Ganaxolone Any
Slide 15: Durable Seizure Improvements in the Open Label Extension
Ganaxolone’s Potential to Provide Durable Seizure Improvements in the Open Label Extension 70 Patients treated with ganaxolone for approximately 12 months experienced a median 52.7% reduction in major motor seizure frequency 60 50 40 Patients transitioning from placebo to ganaxolone demonstrated sei
Slide 16: Average Ganaxolone Levels Correlate with Seizure Reduction
Average Ganaxolone Levels Correlate with Seizure Reduction Loge percentage change in major motor seizure frequency was calculated as loge(percentage change + 100) 16 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Equivalent % Change in Major Motor Seizure Frequency Loge Percent Change Major Mo
Slide 17: PCDH19 Related Epilepsy
PCDH19 Related Epilepsy ©2021 Marinus Pharmaceuticals. All Rights Reserved I
Slide 18: Biomarker Stratified Proof of Concept Study in PCDH19
Biomarker Stratified Proof of Concept (POC) Study in PCDH19 Low Allo-S Placebo R 1:1 Biomarker + Ganaxolone Up to 600 mg 3x/day PCDH19 (all-patients) n=21 Ganaxolone Up to 600 mg 3x/day High Allo-S Biomarker - Placebo R 1:1 Ganaxolone Up to 600 mg 3x/day Primary efficacy analyses conducted using all
Slide 19: Directional Improvement in Change in Seizure Frequency
Ganaxolone Demonstrates Directional Improvement in Change in Seizure Frequency 90 80 70 60 (median) Ganaxolone 14.5 Placebo 17.7 50 40 30 20 10 0 Ganaxolone (n=10) Placebo (n=11) 19 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Percent Reduction in Primary Endpoint Seizure Frequency (per 28 d
Slide 20: Ganaxolone Response Independent of Biomarker Status
Ganaxolone Response Independent of Biomarker Status 20 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Percent Reduction in Primary Endpoint Seizure Frequency (per 28 days) Primary endpoint seizure types are defined as countable focal seizures with impaired awareness or generalized seizure with
Slide 21: Phase 2 Safety Summary
Phase 2 Safety Summary TEAE: treatment emergent adverse event *Patients in the placebo group had a higher frequency of hospitalizations during baseline 21 ©2021 Marinus Pharmaceuticals. All Rights Reserved I ► Ganaxolone was generally well-tolerated • One GNX patient discontinued study due to an SAE
Slide 22: Tuberous Sclerosis Complex
Tuberous Sclerosis Complex “Many individuals with TSC continue to experience uncontrolled seizures despite a cocktail of multiple antiepileptic drugs. Because new options are always needed, the TSC community welcomes clinical evaluation of new epilepsy treatments” - Kari Luther Rosbeck, President &
Slide 23: Tuberous Sclerosis Complex (TSC)
Tuberous Sclerosis Complex (TSC) 1 diMichele, et al, J. Neuro Neurosurg Psychiatry, 2003 *Failure of two prior antiseizure medications with ongoing, frequent seizures. 23 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Cause •Defect or mutation of TSC1 and/or TSC2 genes Symptoms •Benign tumors,
Slide 24: TSC Phase 2 Open-Label Clinical Trial Design
TSC - Phase 2 Open-Label Clinical Trial Design (24 Weeks) Baseline Period Treatment Period OLE Period 2-week taper upon GNX discontinuation (if not continuing to Part B) Baseline Treatment Visit Screening Visit ► n = Approx. 25 ► 8 U.S. sites ► Electronic diaries will be used for data capture ► At l
Slide 25: Proposed Phase 3 TSC Study Design
Proposed Phase 3 TSC Study Design Historical Data (if available) 8 weeks Titration 4 weeks Titration 4 weeks Baseline 4 weeks Maintenance 12 weeks Open-Label Phase Double-Blind Phase Open-Label Phase Trial Details ► Evaluates the use of oral ganaxolone in children and adults with seizures associated
Slide 26: Formulation Development
Formulation Development MARINUS
Slide 27: Efforts to Improve Ganaxolone Exposure in Chronic Epilepsies
Efforts to Improve Ganaxolone Exposure in Chronic Epilepsies Dosing regimen: Marigold Study was the first Phase 3 study of ganaxolone to evaluate three times a day (TID) dosing ► • Predicted pharmacokinetic (PK) curves for TID and two times a day (BID) dosing demonstrate increase trough GNX levels w
Slide 28: Ganaxolone Formulation Work for Second Generation Candidate
Ganaxolone Formulation Work in Progress for Second Generation Candidate Oral Dosing IV Dosing Step down IV to oral Pediatric Dosing 28 ©2021 Marinus Pharmaceuticals. All Rights Reserved I •Exploring opportunities to improve bioavailability and PK profile •Potential expansion into new indications and
Slide 29: Commercial Opportunity
Commercial Opportunity ©2021 Marinus Pharmaceuticals. All Rights Reserved I
Slide 30: Commercialization Preparedness
Commercialization Preparedness Executing research with Payers and Physicians around TPP* / Value Proposition Identifying organizational needs for field resources, systems and processes Development plans to scale up access, scientific affairs and commercial teams Readying supply chain to support pati
Slide 31: Market Research Findings on Ganaxolone Clinical Adoption
Key Findings from Recently Conducted Market Research Show that Ganaxolone is Well Suited for Broad Clinical Adoption Across Indications Reactions Usage Drivers Source: ZS Associates Primary Research and Analysis (N=35 HCP Interviews) 31 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Awareness
Slide 32: Status Epilepticus
Status Epilepticus ©2021 Marinus Pharmaceuticals. All Rights Reserved I
Slide 33: Status Epilepticus (SE): Definition and Epidemiology
Status Epilepticus (SE): Definition and Epidemiology Background Prolonged continuous seizures ► Heterogenous patient population with various etiologies, including glioblastoma, vascular disease, encephalitis, drug or alcohol withdrawal or overdose ► SE is the second most common neurologic emergency
Slide 34: Goals of a New Therapy for the Treatment of SE
Goals of a New Therapy for the Treatment of SE Epilepticus (ESE) Epilepticus (RSE) Epilepticus (SRSE) IV GNX Administered (antiepileptic drugs) 34 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Medically induced Coma Established StatusRefractory StatusSuper Refractory Status 1st line2nd line3r
Slide 35: PK/PD Well Suited for Acute SE Treatment
Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice EEG bispectral index in healthy volunteers following IV ganaxolone Ganaxolone activates the extrasynaptic GABAA receptor, is associated with high brain concentratio
Slide 36: Phase 2 RSE Trial Design
Phase 2 RSE Trial Design Evaluate IV ganaxolone in refractory SE patients SE Patients require escalation of treatment with IV Secondary: Additional efficacy, safety 36 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Endpoints Primary: Percent of patients who did not anesthetic within the first
Slide 37: Patient Demographics of Phase 2 Trial
Patient Demographics of Phase 2 Trial Mean age: 57 years old first-and-second line IV AEDs 37 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Mean # of failed (including benzodiazepines) 2.9 (range: 2-5) Mean # of failed 2nd-line IV AEDs • 2.1 (range: 1-4), all failed LEV or LAC • 14/17 patient
Slide 38: Phase 2 Trial Results Demonstrated Rapid Onset and Durability
Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect No escalation to additional IV AEDs or IV anesthetics for status relapse at any time through 24 hours after ganaxolone discontinuation No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) S
Slide 39: PK/PD Relationship and Rationale for Target Dose
PK/PD Relationship and Rationale for Target Dose Data presented at AES 2019 PK: Pharmacokinetics / PD: Pharmadynamic 39 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Seizure Burden Reduction Occurred Rapidly in All Dose Groups Only High Dose Provided Sustained Reduction (>80%) Throughout Enti
Slide 40: IV Ganaxolone Safety Summary
IV Ganaxolone Safety Summary •9 severe (respiratory depression, death due to Intubation: 9 patients were not intubated upon enrollment. Of these, 6 remained intubation-free during the entire ganaxolone treatment period Data presented at AES 2019 AE: adverse event / SAE: serious adverse event 40 ©202
Slide 41: Overview of U.S. Phase 3 RSE RAISE Trial Design
Overview of U.S. Phase 3 RSE RAISE Trial Design • Status epilepticus patients (n=124) who have failed benzodiazepines and ≥ 2 IV AEDs Co-primary endpoints 41 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Trial design • Randomized, placebo-controlled (adjunctive to standard-of-care) clinical t
Slide 42: RSE Phase 3 RAISE Clinical Planning
RSE Phase 3 RAISE Clinical Planning Phase 3 Target Plasma Concentration S C R E E N I N G Continuous Infusion Dose Initiation (Time 0) 42 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Trial Overview •1:1 randomized, double-blind, placebo-controlled trial •Failure of a benzodiazepine and 2 sec
Slide 43: RAISE Trial Sites Standard of Care
RAISE Trial Sites Standard of Care Progression to IV Anesthesia Surveyed PI’s at selected RAISE Trial sites to learn more about their standard of care natural history progression to IV anesthesia following the failure of one versus more than one 2nd-line IV AEDs ► population Of those that escalate t
Slide 44: BARDA Contract – Refractory Status Epilepticus
BARDA Contract – Refractory Status Epilepticus Key Contract Parameters BARDA to contribute $21 million in base contract to support the Phase 3 RAISE clinical trial in RSE and preclinical studies of ganaxolone in nerve agent exposure animal models. ► BARDA may contribute up to an additional $30 milli
Slide 45: Commercial Opportunity
Commercial Opportunity ©2021 Marinus Pharmaceuticals. All Rights Reserved I
Slide 46: Quantifying the Clinical and Economic Burden of RSE
Quantifying the Significant Clinical and Economic Burden of RSE The Phase 3 trial of ganaxolone in refractory SE aims to demonstrate rapid onset of action capable of preventing escalation to IV anesthetics, and downstream associated clinical outcomes Treatment with IV anesthetics has been reported t
Slide 47: High Cost of Care Currently Associated with RSE Population
High Cost of Care Currently Associated with RSE Population Ganaxolone may provide an opportunity to reduce hospital costs and save lives by altering how medicine is practiced Clinical Outcomes Utilization and Cost Outcomes (≥ 1 IV (≤ 1 IV AED) (> 1 IV AED) (100) 0.2 0.2 0.4 infectionŦ (%) Manuscript
Slide 48: Additional Commercial Opportunities Along SE Continuum
Additional Commercial Opportunities Along SE Continuum Potential to leverage future hospital sales force to address > 3x patient population in ESE & SRSE ESETT 1. DeLorenzo RJ Pellock JM Towne AR Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995; 12: 316-325 2. Kapur et al. Ran
Slide 49: Established Status Epilepticus – Potential Use in Emergency Room
Established Status Epilepticus – Potential Use of Ganaxolone in Emergency Room Room 49 ©2021 Marinus Pharmaceuticals. All Rights Reserved I • Unique Environment: -No EEG -Risk of rapid escalation of care -Convulsive patients: new dosing paradigm – bolus and short infusion time (2-24 hours) Emergency
Slide 50: Proposed ESE Clinical Trial Design
Established Status Epilepticus – Potential Use of Ganaxolone in Emergency Room Proposed ESE Clinical Trial Design Failed benzodiazepine Bolus IV ganaxolone infusion Pilot: N = 4-5 per cohort Open Standard of care IV AED Bolus IV ganaxolone: Failed benzodiazepine Blinded: N = 40 per arm 1:1 Placebo b
Slide 51: Intellectual Property
Intellectual Property
Slide 52: Multiple Layers of Potential Protection
Multiple Layers Of Potential Protection Orphan drug designations for CDD and PCDH19 provide 7 and 10 years regulatory exclusivity in US and EU, respectively. Orphan drug designation for SE provides 7 years regulatory exclusivity in US. 52 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Patent/P
Slide 53: Thank You
ET pe ae Thank 1ou MARINUS PHARMACEUTICALS
Slide 54: Subject Baseline Demographics & Country Enrollment in Marigold Study
Subject Baseline Demographics & Country Enrollment in Marigold Study (CDD) 42 US 15 14 10 IT RU PL UK 7 6 6 1 FR AU IL 54 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Demographic Placebo (n=51) Ganaxolone (n=50) Total (n=101) Age, median 7.0 5.0 6.0 Gender, n (%) Male 10 (19.6) 11 (22.0) 21
Slide 55: Responder Analysis – Marigold Study
Responder Analysis – Marigold Study 55 ©2021 Marinus Pharmaceuticals. All Rights Reserved I Percent Reductions in Major Motor Seizure Frequency
Slide 56: Unmet Need in TSC Epilepsy and Scientific Rationale for Ganaxolone
Unmet Need in TSC Epilepsy and Scientific Rationale for Ganaxolone ► Epilepsy present in ~90% of individuals affected with TSC1 ► Existing treatments fail to control seizures in ~60% of individuals with TSC-associated epilepsy2 ► Uncontrolled seizures, especially early in life, may lead to developme
Slide 57: Details on Baseline Patient Characteristics for Phase 2 SE Trial
Details on Baseline Patient Characteristics for Phase 2 SE Trial 1 Low Vascular No NCSE LAC, LEV 200mg (200-600mg) 3 Low Vascular No NCSE LOR, LAC, LEV 600mg (200-600mg) NCSE: Non-convulsive status epilepticus 5 Low Tumor No CSE LOR, LAC, LEV 2,000mg (1000-3000mg) CSE: Convulsive status epilepticus
Slide 58: Potential Launch Into the Hospital Setting
Potential Launch Into the Hospital Setting Designed to be Driven by Data, Customer Collaboration & Protocolization of Ganaxolone in RSE Critical Success Factors for RSE Launch Clinical and Economic Evidence Access Society Guideline & Account Protocol Inclusion Experienced Hospital Sales Force • Phas
Marinus Pharmaceuticals — Investor Presentation (March 2021) on 6ix